We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » TEVA, ALPHARMA DEAL COULD SPEED GENERIC NEURONTIN
TEVA, ALPHARMA DEAL COULD SPEED GENERIC NEURONTIN
May 4, 2004
Teva Pharmaceutical and Alpharma have agreed to share a portion of Alpharma’s 180-day market exclusivity period for a version of Pfizer’s epilepsy drug Neurontin (gabapentin) — a move that could expedite generic competition on the profitable drug, according to an analyst.